AM
GILD icon

Atwater Malick’s Gilead Sciences GILD Stock Holding History

Atwater Malick’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Buy
2,245
+298
+15% +$39.3K 0.06% 101
2026
Q1 		$271K Sell
1,947
-131
-6% -$18.3K 0.07% 83
2025
Q4 		$255K Buy
+2,078
New +$253K 0.07% 77
2019
Q4 		– Sell
-1,175
Closed -$74K – 101
2019
Q3 		$74K Buy
+1,175
New +$76.8K 0.06% 58

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atwater Malick's GILD Position: Q2 2026 in Review

Atwater Malick increased its Gilead Sciences (GILD) stake by 15% in Q2 2026, buying an estimated $39.3K and bringing the position to 2,245 shares worth $284K. The position accounts for 0.06% of the portfolio, ranked #101.

Atwater Malick first reported a position in GILD in Q3 2019 and has held it in 4 quarters since. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Atwater Malick held 2,245 shares of Gilead Sciences worth $284K as of Q2 2026.
  • Atwater Malick bought 298 Gilead Sciences shares in Q2 2026, an estimated $39.3K.
  • Gilead Sciences made up 0.06% of Atwater Malick's portfolio in Q2 2026, its #101 holding.
  • Atwater Malick first reported a position in Gilead Sciences in Q3 2019 and has held it in 4 quarters since.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Atwater Malick's 13F filing for Q2 2026, filed 27 Jul 2026.